Meeting
2016 ASCO Annual Meeting
Rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer.
Authors
Lee Steven Schwartzberg
The West Clinic, Memphis, TN
Lee Steven Schwartzberg , Rudolph M. Navari , Sujata Arora , Daniel Powers , Karin Jordan , Bernardo Leon Rapoport
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01500226
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10121)
DOI
10.1200/JCO.2016.34.15_suppl.10121
Abstract #
10121
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety of intravenous (IV) NEPA and oral NEPA for prevention of CINV in patients (pts) with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy (CT).
First Author: Lee S. Schwartzberg
Poster
2019 Supportive Care in Oncology Symposium
Antiemetic efficacy of intravenous (IV) NEPA in patients with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy.
First Author: Lee S. Schwartzberg
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy.
First Author: Rudolph M. Navari
Poster
2015 Palliative and Supportive Care in Oncology Symposium
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in non–anthracycline/cyclophosphamide (AC)-based moderately emetogenic therapy (MEC).
First Author: Daniel Powers